Anthony Petrone
Stock Analyst at Jefferies
(3.92)
# 563
Out of 4,774 analysts
163
Total ratings
51.28%
Success rate
8.45%
Average return
Main Sectors:
Stocks Rated by Anthony Petrone
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TARS Tarsus Pharmaceuticals | Maintains: Buy | $54 → $58 | $49.91 | +16.21% | 2 | Mar 6, 2025 | |
| LIVN LivaNova | Maintains: Outperform | $70 → $60 | $40.43 | +48.40% | 8 | Feb 26, 2025 | |
| GKOS Glaukos | Upgrades: Outperform | $140 → $200 | $100.63 | +98.75% | 7 | Feb 19, 2025 | |
| HOLX Hologic | Maintains: Outperform | $90 → $87 | $61.01 | +42.60% | 8 | Nov 5, 2024 | |
| TFX Teleflex | Maintains: Neutral | $275 → $250 | $139.43 | +79.30% | 7 | Nov 1, 2024 | |
| BSX Boston Scientific | Maintains: Outperform | $100 → $110 | $101.51 | +8.36% | 8 | Oct 24, 2024 | |
| ABT Abbott Laboratories | Maintains: Neutral | $115 → $130 | $126.78 | +2.54% | 4 | Oct 17, 2024 | |
| ADMA ADMA Biologics | Maintains: Buy | $12 → $14 | $19.65 | -28.75% | 6 | Jun 20, 2024 | |
| ESTA Establishment Labs Holdings | Maintains: Buy | $65 → $70 | $39.46 | +77.39% | 6 | Jun 6, 2024 | |
| ALC Alcon | Maintains: Buy | $100 → $105 | $91.37 | +14.92% | 8 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $53 → $55 | $17.92 | +206.92% | 7 | May 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $90 → $100 | $98.85 | +1.16% | 5 | May 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $110 → $105 | $81.81 | +28.35% | 6 | May 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $20 → $16 | $5.78 | +176.82% | 3 | Apr 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $95 → $105 | $70.95 | +47.99% | 7 | Apr 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $215 | $221.11 | -2.76% | 15 | Mar 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $250 | $162.75 | +53.61% | 6 | Mar 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $13 → $14 | $7.97 | +75.66% | 4 | Mar 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $103 → $115 | $80.39 | +43.05% | 14 | Mar 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $95 → $98 | $91.22 | +7.43% | 4 | Feb 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $350 → $390 | $491.81 | -20.70% | 6 | Jan 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $63 → $67 | $85.68 | -21.80% | 2 | Aug 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $110 → $115 | $64.24 | +79.02% | 14 | Feb 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $200 → $175 | $111.78 | +56.56% | 3 | Nov 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $30 → $25 | $12.86 | +94.40% | 3 | May 13, 2020 |
Tarsus Pharmaceuticals
Mar 6, 2025
Maintains: Buy
Price Target: $54 → $58
Current: $49.91
Upside: +16.21%
LivaNova
Feb 26, 2025
Maintains: Outperform
Price Target: $70 → $60
Current: $40.43
Upside: +48.40%
Glaukos
Feb 19, 2025
Upgrades: Outperform
Price Target: $140 → $200
Current: $100.63
Upside: +98.75%
Hologic
Nov 5, 2024
Maintains: Outperform
Price Target: $90 → $87
Current: $61.01
Upside: +42.60%
Teleflex
Nov 1, 2024
Maintains: Neutral
Price Target: $275 → $250
Current: $139.43
Upside: +79.30%
Boston Scientific
Oct 24, 2024
Maintains: Outperform
Price Target: $100 → $110
Current: $101.51
Upside: +8.36%
Abbott Laboratories
Oct 17, 2024
Maintains: Neutral
Price Target: $115 → $130
Current: $126.78
Upside: +2.54%
ADMA Biologics
Jun 20, 2024
Maintains: Buy
Price Target: $12 → $14
Current: $19.65
Upside: -28.75%
Establishment Labs Holdings
Jun 6, 2024
Maintains: Buy
Price Target: $65 → $70
Current: $39.46
Upside: +77.39%
Alcon
May 15, 2024
Maintains: Buy
Price Target: $100 → $105
Current: $91.37
Upside: +14.92%
May 8, 2024
Maintains: Buy
Price Target: $53 → $55
Current: $17.92
Upside: +206.92%
May 3, 2024
Maintains: Buy
Price Target: $90 → $100
Current: $98.85
Upside: +1.16%
May 1, 2024
Maintains: Buy
Price Target: $110 → $105
Current: $81.81
Upside: +28.35%
Apr 11, 2024
Maintains: Neutral
Price Target: $20 → $16
Current: $5.78
Upside: +176.82%
Apr 11, 2024
Maintains: Buy
Price Target: $95 → $105
Current: $70.95
Upside: +47.99%
Mar 27, 2024
Maintains: Buy
Price Target: $215
Current: $221.11
Upside: -2.76%
Mar 27, 2024
Maintains: Buy
Price Target: $250
Current: $162.75
Upside: +53.61%
Mar 1, 2024
Maintains: Buy
Price Target: $13 → $14
Current: $7.97
Upside: +75.66%
Mar 1, 2024
Maintains: Buy
Price Target: $103 → $115
Current: $80.39
Upside: +43.05%
Feb 21, 2024
Maintains: Buy
Price Target: $95 → $98
Current: $91.22
Upside: +7.43%
Jan 25, 2024
Maintains: Neutral
Price Target: $350 → $390
Current: $491.81
Upside: -20.70%
Aug 3, 2023
Downgrades: Hold
Price Target: $63 → $67
Current: $85.68
Upside: -21.80%
Feb 8, 2023
Maintains: Buy
Price Target: $110 → $115
Current: $64.24
Upside: +79.02%
Nov 5, 2021
Maintains: Buy
Price Target: $200 → $175
Current: $111.78
Upside: +56.56%
May 13, 2020
Maintains: Hold
Price Target: $30 → $25
Current: $12.86
Upside: +94.40%